Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker VSTM · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer NCT07659782 · Non-Small Cell Lung Cancer VS-7375 | VSTM Verastem, Inc. | Phase 2 | Recruiting | 105 | Jun 2027 | Registry ↗ |
| Nov 13, 2026 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer NCT07644559 · Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS VS-7375, cetuximab (or panitumumab if α-gal IgE+ or cetuxim… | VSTM Verastem, Inc. | Phase 2 | Recruiting | 185 | Jun 2027 | Registry ↗ |
| Nov 12, 2026 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer NCT07659795 · Colorectal Cancer VS-7375, cetuximab | VSTM Verastem, Inc. | Phase 2 | Recruiting | 150 | Jun 2027 | Registry ↗ |
| Nov 10, 2026 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors NCT07020221 · Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer VS-7375, Cetuximab | VSTM Verastem, Inc. | Phase 1/2 | Recruiting | 616 | Dec 2028 | Registry ↗ |
| Nov 2, 2026 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Canc… NCT06072781 · Low Grade Serous Ovarian Cancer avutometinib, Defactinib | VSTM Verastem, Inc. | Phase 3 | Recruiting | 270 | Oct 15, 2028 | Registry ↗ |
| Aug 5, 2026 | Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grad… NCT07747506 · Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer avutometinib + defactininb combination | VSTM Verastem, Inc. | Phase 2 | Not yet recruiting | 2 | Aug 1, 2027 | Registry ↗ |
| Jul 2, 2026 | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients NCT05375994 · Non Small Cell Lung Cancer, KRAS Activating Mutation avutometinib (VS-6766) and adagrasib | VSTM Verastem, Inc. | Phase 1/2 | Completed | 12 | Jun 15, 2026 | Registry ↗ |
| Jan 12, 2026 | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC… NCT05074810 · Non Small Cell Lung Cancer, KRAS Activating Mutation avutometinib and sotorasib, avutometinib and sotorasib and… | VSTM Verastem, Inc. | Phase 1/2 | Active, not recruiting | 153 | Jun 2026 | Registry ↗ |
| Dec 17, 2025 | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patie… NCT06682572 · Low Grade Serous Ovarian Cancer, Ovarian Cancer Avutometinib (VS-6766) + Defactinib (VS-6063) | VSTM Verastem, Inc. | Phase 2 | Active, not recruiting | 16 | Dec 2025 | Registry ↗ |
| Sep 2, 2025 | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pa… NCT05669482 · KRAS Activating Mutation, Metastatic Cancer avutometinib (VS-6766) and defactinib in combination with g… | VSTM Verastem, Inc. | Phase 1/2 | Active, not recruiting | 40 | Aug 31, 2026 | Registry ↗ |
| Jan 29, 2025 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Ser… NCT04625270 · Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer avutometinib (VS-6766), avutometinib (VS-6766) and defactin… | VSTM Verastem, Inc. | Phase 2 | Active, not recruiting | 225 | Nov 15, 2024 | Registry ↗ |
| Feb 20, 2024 | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesoth… NCT02004028 · Malignant Pleural Mesothelioma VS-6063 | VSTM Verastem, Inc. | Phase 2 | Terminated | 35 | Jun 19, 2019 | Registry ↗ |
| Jan 12, 2024 | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Smal… NCT04620330 · Non Small Cell Lung Cancer, KRAS Activating Mutation avutometinib (VS-6766), avutometinib (VS-6766) and Defactin… | VSTM Verastem, Inc. | Phase 2 | Completed | 90 | Aug 29, 2023 | Registry ↗ |
| May 10, 2022 | Food Effect of VS-6766 in Healthy Adult Subjects NCT05187169 · Food Effect VS-6766 | VSTM Verastem, Inc. | Phase 1 | Completed | 18 | Apr 12, 2022 | Registry ↗ |
| Apr 30, 2019 | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activi… NCT02943317 · Epithelial Ovarian Cancer Part A - VS-6063, Part A - Avelumab | VSTM Verastem, Inc. | Phase 1 | Terminated | 98 | Aug 28, 2018 | Registry ↗ |
| Jul 28, 2017 | Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies NCT01849744 · Non Hematologic Cancers, Metastatic Cancer VS-4718 | VSTM Verastem, Inc. | Phase 1 | Terminated | 48 | Apr 2017 | Registry ↗ |
| Jul 27, 2017 | Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advan… NCT02651727 · Pancreatic Cancer Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine, Par… | VSTM Verastem, Inc. | Phase 1 | Terminated | 13 | Jan 2017 | Registry ↗ |
| May 17, 2017 | Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer NCT01778803 · Ovarian Cancer defactinib, Paclitaxel | VSTM Verastem, Inc. | Phase 1 | Completed | 22 | Feb 23, 2015 | Registry ↗ |
| Apr 13, 2017 | Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer NCT01951690 · Non Small Cell Lung Cancer, Lung Cancer defactinib (VS-6063) | VSTM Verastem, Inc. | Phase 2 | Completed | 55 | Jun 2016 | Registry ↗ |
| Mar 9, 2017 | Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies NCT01943292 · Non Hematologic Cancers Defactinib | VSTM Verastem, Inc. | Phase 1 | Completed | 9 | Jun 9, 2014 | Registry ↗ |
| Jan 30, 2017 | A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Hea… NCT02913716 · Healthy Subjects defactinib | VSTM Verastem, Inc. | Phase 1 | Completed | 5 | Sep 2015 | Registry ↗ |
| Jan 30, 2017 | A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects Wi… NCT02372227 · Relapsed Malignant Mesothelioma VS-5584 and VS-6063 | VSTM Verastem, Inc. | Phase 1 | Terminated | 21 | Oct 2015 | Registry ↗ |
| Jan 30, 2017 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma NCT01870609 · Malignant Pleural Mesothelioma defactinib (VS-6063), Placebo | VSTM Verastem, Inc. | Phase 2 | Terminated | 344 | Jan 2016 | Registry ↗ |
| Jan 27, 2017 | Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia NCT02215629 · Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or… VS-4718 | VSTM Verastem, Inc. | Phase 1 | Withdrawn | 0 | Sep 2016 | Registry ↗ |
| Jan 27, 2017 | Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or… NCT01991938 · Non Hematologic Cancers, Metastatic Cancer VS-5584 | VSTM Verastem, Inc. | Phase 1 | Terminated | 75 | Dec 2016 | Registry ↗ |
| Jan 25, 2017 | A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies NCT00787033 · Cancer PF-04554878 | VSTM Verastem, Inc. | Phase 1 | Completed | 46 | Mar 2011 | Registry ↗ |
26 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 5:55 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances